[Personal experience with 200mg of micronized fenofibrate (Lipanthyl 200 M) in the treatment of primary dyslipidemias].
Micronized phenofibrate 200 mg was administered in clinical trial to 30 patients with dyslipidaemia. Their average age was 51.9 years (10 with type 2a, 12 with type 2b and 8 with types 4 and 5). After 12 weeks of treatment significant improvement of the whole lipid profile was achieved. The total cholesterol declined in different sub-groups by 16, 17 and 20% resp. LDL cholesterol declined by 20 and 18 per cent in types 2a and 2b, in types 4 and 5 it was not assessed (it was not possible to use Friedewald's equation). Triglycerides declined by 39, 45 and 75%. The HDL concentration increased by 16, 27 and 25%. The atherogenic indexes TCh/HDL-Ch declined by 28, 36 and 32%. LDL-Ch/HDL-Ch dropped by 30 and 34%. The extent of the hypolipidaemic effect depended on the baseline value: the more pathological the baseline value, the more marked the improvement. As to other investigated indicators there was a significant rise of the apolipoprotein AI and Lp AI particle concentration. Apoprotein B declined insignificantly. Uric acid declined significantly by 28%. Fibrinogen dropped significantly only in type 2a. The lipoprotein(a) concentration did not change significantly. The drug was very well tolerated and undesirable effects were minimal. Micronized phenofibrate (Lipanthyl 200 M) due to its comprehensive favourable effect on the entire lipid profile and other risk factors can prove useful in the treatment of all types of dyslipidaemias (with the exception of type I). As compared with Lipanthyl 100, the better pharmacokinetic properties make it possible to reduce the dose from 300 mg/day and it can be administered in a single daily dose.